UNH 10-K Analysis: Why UnitedHealth's Medical Cost Crisis Is Worse Than Peers

UnitedHealth Group — the largest healthcare company in America, with $448 billion in annual revenue and 90,000 physicians under its Optum umbrella — grew Medicare Advantage membership by 600,000 in FY2025. Operating income fell 41%. The medical cost ratio hit 89.1%, the worst trajectory among five managed care peers.

By every growth measure, FY2025 should have been a strong year. Revenue surpassed $447 billion, up 12%. Medicare Advantage, the company's largest insurance line, added members. Optum continued serving 95 million people. UnitedHealthcare's premium revenue crossed $352 billion. If you stopped at the top line, you'd see the compounder thesis intact.

But the FY2025 10-K, filed March 2, 2026, reveals what the growth headlines obscure. Medical costs grew 30% over two years while premiums grew 21% — a widening gap that no amount of revenue growth can close. We extracted the medical cost ratio from all five major managed care companies' raw 10-K filings to see whether UNH's crisis is industry-wide or company-specific. The answer is both — but UNH's +5.9 percentage point deterioration is nearly double the peer average of +3.5pp. These aren't reasons to sell. They're the specific conditions that determine whether 24.9x trailing earnings is a buying opportunity or a value trap.

The Numbers Behind the Drop

UNH's medical care ratio — the percentage of premium revenue consumed by medical claims — has accelerated for three consecutive fiscal years. In FY2023, the ratio stood at 83.2%, among the best in the managed care industry. By FY2025, it reached 89.1%. That 5.9 percentage point swing means an additional $21 billion in medical costs annually relative to the 2023 cost structure.

The trend is not subtle. Medical costs grew 30% over two years while premium revenue grew 21%. Prior year favorable development — the cushion from overestimated reserves in prior periods — collapsed from $840 million to $140 million, removing the buffer that had masked the underlying cost acceleration in earlier years.

"For 2025, our pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred, significantly impacting our financial results."

Management's admission is unusually direct: they mispriced risk. UnitedHealth Group's medical cost ratio hit 89.1% in FY2025, a 5.9 percentage point increase over two years that turned 12% revenue growth into a 41% operating income decline as pricing assumptions fell "well-short" of actual medical cost trends.

The Membership Paradox

Here is the counterintuitive fact that reframes the entire crisis: Medicare Advantage membership grew by 600,000 in FY2025 — a 7.6% increase. UnitedHealthcare's revenue climbed 15.7% to $344.9 billion. The narrative that UNH is "losing members" is forward-looking guidance for 2026, not a description of what happened in 2025.

The FY2025 earnings collapse happened with growing membership and growing revenue. This is worse, not better, than a simple demand problem. It means the existing book of business is structurally unprofitable at current cost levels.

"The MCR increased as a result of the revenue effects of the Medicare funding reductions, elevated medical cost trend, the member profile of newly added patients under value-based care arrangements, the acceleration of anticipated future losses in 2026 related to certain Optum Health value-based care contracts, decreased favorable development, the impacts of the IRA on Medicare Part D and the impacts of market morbidity changes on our individual exchange offerings."

Management's list of MCR drivers is long — but two items stand out. First, "the member profile of newly added patients" suggests the 600,000 new members were sicker and more expensive than anticipated. Second, "the acceleration of anticipated future losses in 2026" means management is already recognizing that next year's contracts will be unprofitable, which is why a $672 million premium deficiency reserve — a line item that never existed in prior years — appeared for the first time. UnitedHealth grew Medicare Advantage membership by 600,000 in FY2025 while operating income fell 41%, and a first-ever $672 million premium deficiency reserve signals management expects specific contracts to lose money in 2026.

What Five Filings Reveal About the Industry

Is UNH's medical cost crisis an industry-wide problem or a company-specific failure? To answer this, we extracted the medical cost ratio — or its equivalent metric — from the raw 10-K XBRL filing data of all five major managed care companies for three consecutive fiscal years. Each company uses a different term: UNH reports "medical care ratio," Elevance Health calls it "benefit expense ratio," Cigna uses segment-level MCR, Humana reports "benefit ratio," and CVS Health calls it "medical benefit ratio." The definitions aren't perfectly comparable — Elevance includes quality improvement costs, Cigna's figures reflect its March 2025 Medicare Advantage divestiture — but the directional trends are clear.

The answer is both — and that's what makes the data useful. All five companies saw MCR increases, confirming a real industry headwind from Medicare funding reductions, medical cost inflation, and the Inflation Reduction Act's Part D redesign. But UNH's +5.9 percentage point deterioration is 1.7 times the peer average of +3.5pp. UNH went from having the best MCR in the group (83.2% in FY2023) to having the steepest trajectory.

Consider the outliers. Cigna kept its MCR below 85% — the best absolute level — by divesting its Medicare Advantage business to HCSC in March 2025, removing the most volatile cost exposure entirely. CVS, despite the worst absolute ratio at 91.2%, is actually recovering — its MBR improved 1.3 percentage points from 92.5% in FY2024. Humana, the most Medicare Advantage-concentrated peer at roughly 80% of revenue, increased only 2.9 percentage points, half of UNH's deterioration.

Of the eight Tier A findings from our filing analysis, three are unique to UNH, three are partially unique (same trend but UNH worst), and two are industry-wide. UNH's MCR deterioration of 5.9 percentage points from 2023 to 2025 is nearly double the 3.5 percentage point average across four managed care peers (ELV, CI, HUM, CVS), based on medical cost ratios extracted from all five companies' raw 10-K filing data. The industry headwind is real — but something about UNH amplifies it.

When the Flywheel Reverses

That something is the vertical integration model. UnitedHealthcare doesn't just pay external providers when members get sick — it pays Optum. In FY2025, intercompany transactions between UNH's insurance and services arms reached $168 billion, representing 27% of the company's gross revenue. This internal flywheel grew 11.3% year-over-year, roughly matching consolidated revenue growth, which means the transmission mechanism is getting stronger, not weaker.

When medical costs rise at UnitedHealthcare, UNH gets hit twice. The insurance side absorbs the claims expense directly — driving the MCR from 83.2% to 89.1%. But the services side absorbs it too, because Optum Health's value-based care contracts mean it bears the financial risk of patient outcomes. If the patients cost more than expected, Optum Health loses money on those contracts. In FY2025, Optum Health posted an operating loss of $278 million — and even adding back $1.7 billion in restructuring charges, the adjusted margin collapsed from 7.4% to 1.4%.

"Premium revenues from CMS represented 44% of UnitedHealth Group's total consolidated revenues for the year ended December 31, 2025."

The filing reveals Optum Health is responding by converting risk-based contracts to fee-based contracts — a deliberate strategic retreat from value-based care. This reduces losses but undermines the thesis that UNH's integrated model creates aligned incentives for better outcomes at lower cost. Meanwhile, CMS — a single government payer — represents 44% of total consolidated revenue, concentrating the Medicare funding headwind through every layer of the business. UnitedHealth's $168 billion in annual intercompany transactions transmit medical cost inflation from its insurance arm directly into Optum Health's care delivery business, collapsing the services segment's adjusted margin from 7.4% to 1.4% — a dual-loss mechanism no peer experiences at comparable scale.

The Kitchen-Sink Test

In Q4 2025, management took $2.5 billion in restructuring and other charges — the largest single-quarter action in UNH's history. The natural question: is this a one-time reset that clears the deck for recovery, or a sign that the underlying business has deteriorated beyond what kitchen-sinking can fix?

"In the fourth quarter of 2025 the Company took restructuring and other actions that resulted in a total impact of $2.5 billion, which included real estate rationalization and workforce reductions of $746 million, contractual reassessments of $573 million, the establishment a loss contract reserve related to anticipated future losses in 2026 for certain value-based care businesses of $623 million, net valuation losses on equity securities of $329 million and the advance funding of the United Health Foundation of $250 million."

The decomposition is revealing. The workforce and real estate cuts ($746 million) are genuinely one-time. But the $623 million loss contract reserve is explicitly forward-looking — management is pre-recognizing anticipated losses in 2026 on value-based care contracts. That is not a cleanup of past costs; it is a confession that future contracts are already expected to lose money.

The peer comparison sharpens this. UNH's $2.5 billion restructuring is 3.3 times Cigna's $749 million and 5.6 times Humana's $449 million. Elevance completed its restructuring program in 2023-2024 and actually released $55 million in reserves in FY2025. Even at the adjusted level, UNH's operating margin is the worst trajectory in the peer group. UnitedHealth's $2.5 billion restructuring charge is 3 to 5 times larger than any managed care peer's, yet adjusted operating income excluding restructuring still fell 35% to $20.9 billion — the underlying business deteriorated independently of one-time charges.

Three Numbers to Watch

The thesis — that UNH's integrated model amplifies an industry-wide MCR crisis through $168 billion in intercompany transactions — is falsifiable. Three specific metrics in the next quarterly filings will either confirm or disprove it.

The first threshold is the most consequential. Premium repricing for 2026, benefit cuts, and 190 county exits should partially offset cost trends. If the MCR falls below 87% by the Q2 2026 10-Q, the structural amplification thesis is wrong — the FY2025 deterioration was a pricing lag, not a permanent problem. If it stays above 89%, premium repricing failed and the structural thesis intensifies.

The second threshold tests the services side. Optum Health's risk-to-fee contract conversions should reduce volatility, and the $1.7 billion in FY2025 restructuring stripped out the worst contracts. If Optum Health posts another operating loss even excluding restructuring, the value-based care model is fundamentally broken, not just mispriced.

The third threshold tracks the insurance flywheel. Management guided for Medicare Advantage membership contraction in 2026 — the first decline in the company's history. Humana's guidance of 25% individual MA growth in 2026 suggests UNH's lost members may flow to competitors, not leave Medicare Advantage entirely. If UNH's net loss exceeds 2 million members, the competitive position is eroding faster than repricing can fix.

UNH trades at 24.9 times trailing earnings while peers Elevance Health and Cigna trade at 12 to 14 times, a premium that requires MCR normalization to 85-86% and Optum Health margin recovery to 5% — assumptions the FY2025 10-K does not yet support.

Frequently Asked Questions

Is UNH's medical cost ratio problem temporary or permanent?

The filing data suggests it's partially structural. The MCR has accelerated for three consecutive years (83.2% to 85.5% to 89.1%), management created a $672M loss contract reserve for anticipated 2026 losses, and prior year favorable development collapsed from $840M to $140M. Premium repricing in 2026 should partially offset the trend, but UNH's deterioration is nearly double the peer average.

Why did UNH's earnings collapse if revenue grew 12%?

Revenue grew because Medicare Advantage membership increased (+600K) and premium rates rose. But medical costs grew even faster (+19%), creating a widening gap. Management admitted their pricing assumptions were "well-short of the medical cost trends incurred." Operating income fell 41% despite 12% revenue growth.

Is the medical cost problem industry-wide or specific to UNH?

Both. All five major managed care companies (UNH, ELV, CI, HUM, CVS) saw MCR/BER increases from 2023 to 2025. But UNH's +5.9pp increase is nearly double the peer average of +3.5pp. CI kept its MCR below 85% by divesting Medicare Advantage. The data suggests UNH has a company-specific amplification problem on top of the industry trend.

What is the flywheel amplification problem?

UNH's insurance arm pays its services arm (Optum) for care delivery, creating $168B in annual intercompany transactions (27% of gross revenue). When medical costs rise, UNH gets hit twice: once on the insurance side and again on the Optum Health side. No peer has this dual-exposure at comparable scale.

Should I buy UNH after the drop?

This analysis does not make buy/sell recommendations. At approximately $330 and 24.9x trailing earnings, UNH is priced for significant earnings recovery. Peers trade at 12-14x earnings. The premium requires MCR normalization to 85-86% and Optum Health margin recovery to 5%+. The filing data does not yet support either assumption.

What did Optum Health's value-based care retreat mean?

Optum Health is converting risk-based contracts to fee-based contracts, stepping back from bearing the financial risk of patient outcomes. It reduces losses but undermines the thesis that UNH's integrated model creates a sustainable competitive advantage through aligned incentives.

How does UNH's restructuring compare to peers?

UNH's $2.5B restructuring is 3.3 times Cigna's $749M and 5.6 times Humana's $449M. Elevance completed its program in 2023-2024 and released $55M in reserves in 2025. UNH's restructuring includes a unique $623M loss contract reserve for anticipated future VBC losses — no peer disclosed anything comparable.

What is the $672M premium deficiency reserve?

A new line item in UNH's medical costs payable that never existed in prior years. It represents contracts where expected future claims exceed expected future premiums. Going from $0 to $672M in a single year is a leading indicator of structural unprofitability in specific contract portfolios.

What would make the bull case work?

Three things: MCR reversal to 86-87% by H2 2026, Optum Health margin recovery to 3-4%, and FY2026 revenue stabilization above $420B despite MA membership loss. The Q1 2026 10-Q will be the first real test.

What is the 5-company MCR convergence analysis?

We extracted the medical cost ratio from the raw 10-K XBRL filing data of all five major managed care companies for three consecutive fiscal years. Each company uses a different term and methodology. The cross-company extraction reveals all five converging toward an 87-90% MCR band, but UNH arrived from the lowest starting point with the steepest trajectory.

Methodology

Data Sources

This analysis draws from UnitedHealth Group's FY2025 10-K filed March 2, 2026, supplemented by raw 10-K filing data from four managed care peers: Elevance Health (ELV), Cigna Group (CI), Humana (HUM), and CVS Health (CVS). Quantitative metrics were extracted via the MetricDuck XBRL pipeline from SEC EDGAR filings. All peer MCR/BER data was extracted from raw XBRL R*.htm files and MD&A sections of each company's FY2025 10-K.

Limitations

• MCR definitions are not perfectly comparable across companies. Elevance's benefit expense ratio includes quality improvement costs; Cigna's MCR reflects its post-Medicare Advantage divestiture business mix; Humana's is consolidated across Insurance and CenterWell; CVS's is for the Health Care Benefits (Aetna) segment only. The comparison reveals directional trends, not precise apples-to-apples metrics.
• Cigna divested Medicare Advantage in March 2025 (to HCSC), making its FY2025 MCR artificially lower than a like-for-like comparison would show.
• This analysis covers annual data only. Quarterly MCR trends, which would show seasonal patterns and inflection points, are not available from 10-K filings alone.
• No management interviews, conference call transcripts, or sell-side research were consulted. Analysis is based exclusively on SEC filing data and the MetricDuck data pipeline.

Disclaimer

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in UNH, ELV, CI, HUM, or CVS. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.